Details for Patent: 12,115,179
✉ Email this page to a colleague
Which drugs does patent 12,115,179 protect, and when does it expire?
Patent 12,115,179 protects SYNJARDY XR, TRIJARDY XR, GLYXAMBI, JARDIANCE, and SYNJARDY, and is included in five NDAs.
This patent has forty-two patent family members in thirty-five countries.
Summary for Patent: 12,115,179
Title: | Pharmaceutical composition, methods for treating and uses thereof |
Abstract: | The invention relates to a pharmaceutical composition comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions. |
Inventor(s): | Peter Eickelmann, Michael Mark, Leo John Seman, Leo Thomas, Uli Christian BROEDL, Rolf GREMPLER |
Assignee: | Boehringer Ingelheim International GmbH |
Application Number: | US18/320,462 |
Patent Claim Types: see list of patent claims | |
Patent landscape, scope, and claims: | More… ↓ |
Drugs Protected by US Patent 12,115,179
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Boehringer Ingelheim | SYNJARDY XR | empagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208658-001 | Dec 9, 2016 | RX | Yes | No | 12,115,179 | ⤷ Try for Free | TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN | ⤷ Try for Free | ||||
Boehringer Ingelheim | SYNJARDY XR | empagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208658-002 | Dec 9, 2016 | RX | Yes | No | 12,115,179 | ⤷ Try for Free | TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN | ⤷ Try for Free | ||||
Boehringer Ingelheim | SYNJARDY XR | empagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208658-003 | Dec 9, 2016 | RX | Yes | No | 12,115,179 | ⤷ Try for Free | TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN | ⤷ Try for Free | ||||
Boehringer Ingelheim | SYNJARDY XR | empagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208658-004 | Dec 9, 2016 | RX | Yes | Yes | 12,115,179 | ⤷ Try for Free | TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN | ⤷ Try for Free | ||||
Boehringer Ingelheim | TRIJARDY XR | empagliflozin; linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 212614-001 | Jan 27, 2020 | RX | Yes | No | 12,115,179 | ⤷ Try for Free | TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN | ⤷ Try for Free | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,115,179
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 075421 | ⤷ Try for Free | |||
Australia | 2010212867 | ⤷ Try for Free | |||
Brazil | PI1008560 | ⤷ Try for Free | |||
Canada | 2751834 | ⤷ Try for Free | |||
Chile | 2011001735 | ⤷ Try for Free | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |